Accum™ technology in early cancer trials and beyond

Many of the latest anti-cancer drugs are targeted towards the tiniest molecular differences in cells. But even if you know the genetic make up of a tumour, getting medicines to - and then in to - the affected area is a different challenge.Dr Moutih Rafei at Defence Therapeutics reports on a novel drug technology that gets more treatment to the cells that need it,  and what that might mean for the future of designing, trialling, and marketing medicines.Read the original research: https://doi.org/10.1111/cas.15985